

study of HIV-1 transmitted drug resistance, filled questionnaires were obtained for 440 patients. Homosexual contact as the most probable mode of HIV acquisition reported 326/440 patients. Subsequently, partial *pol* sequences were obtained for 252 MSM patients who were included in the present study. Sequences were analyzed using the following automatic subtyping tools: REGA 2.0, REGA 3.0, COMET HIV-1 1.0, jpHMM, and SCUEAL. Sequences that gave divergent subtyping results were considered to be potential recombinant forms. Temporal trend of the proportion of non-B and potential recombinant sequences (both combined termed as “non-pure subtype B” sequences) was evaluated with Fisher exact test used for the assessment of statistical significance. All five subtyping tools gave concordant subtyping results in 230/252 (91.3%) of sequences. Pure subtype B was assigned to 226/252 (89.7%) sequences and subtype A, subtype C, subtype F and CRF01_AE were determined in one patient each (0.4%). The remaining 22/252 (8.7%) sequences yielded divergent results with at least one of the subtyping tools, an indication to a possible recombination event in the past. An increase in the proportion of “non-pure subtype B” HIV-1 variants was noted over the years with 0% (95% confidence interval (CI): 0–16%), 5% (95% CI: 1–15%), 4% (95% CI: 0–13%), 11% (95% CI: 4–21%), and 25% (95% CI: 15–39%) determined in the years 2000–2, 2003–5, 2006–8, 2009–11, and 2012–4, respectively. The marked increase was on account of an increasing number of potential recombinant sequences with subtype B as one of the founder subtypes, since this subtype was identified in 21/22 of divergent sequences. The remaining divergent sequence was a complex recombinant containing subtypes D and G. Additionally, all 4 pure non-B subtyped sequences were determined in patients diagnosed in the last two years (2013–4). The results obtained indicate that subtypes other than B are entering the HIV-1 MSM epidemic in Slovenia, making recombination events among different subtypes more plausible. A marked increase in the numbers of non-B subtypes and potential recombinant forms was observed among MSM in Slovenia in recent years.

A23 Identification of HIV drug resistance mutation patterns using illumina MiSeq next generation sequencing in patients failing second-line boosted protease inhibitor therapy in Nigeria

Onyemata E. James,¹ Ledwaba Johanna,³ Datir Rawlings,¹ M. Babajehson,¹ Ismail Ashrad,³ Derache Anne,⁴ Alash'le Abimiku,^{1,2} Patrick Dakum,¹ Hunt Gillian,³ Nicaise Ndembi,¹

¹Institute of Human Virology - Nigeria, Abuja, Federal Capital Territory, Nigeria, ²Institute of Human Virology, University of Maryland School of Medicine, MD, USA, ³AIDS Research Unit, National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa and ⁴Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa

There is limited information of patterns of protease inhibitor (PI) resistance in adults failing second-line therapy. Next generation sequencing (NGS) detects drug resistance mutations as low as 1%. However, the clinical implications of these minority variants to treatment outcomes are still in debate. Approximately 5% of antiretroviral treatment (ART) exposed patients in our treatment program are on second-line boosted protease inhibitor (PI). Population-based sequencing conducted on some of these patients revealed no major HIV drug resistance mutations (DRMs) to PIs. We compared population-based sequencing and NGS results with the view of identifying patterns of drug resistance mutations and minority variants. Forty-eight plasma samples from 40 patients on second-line

NRTI/NNRTI and boosted PI regimens with evidence of virologic failures ($VL \geq 1,000$ copies/ml) were used in this study. Of these, eight were obtained at the time of first-line failure while the remaining 40 at the time of second-line failure. Ultra-deep sequencing sample preparation was achieved using Illumina Nextera XT protocol. This required that target amplicon be subjected to fragmentation, tagging, indexing, size exclusion bead purification, normalization, and pooling. MiSeq data analysis was performed using the Geneious software by applying 1% cut-off at major drug resistance sites. Electropherogram data were generated using ABI 3130 genetic analyzer and analysis performed using Stanford Genotyping Resistance Interpretation Algorithm available at <http://sierra2.stanford.edu/sierra/servlet/JSierra> and IAS-USA 2015 Drug Resistance Interpretation list. MiSeq sequencing showed that 53% ($n=23$) of the patients developed PI resistance, 93% ($n=40$) had NRTI resistance, and 70% ($n=30$) had NNRTI resistance. Of the DRMs detected in protease, L90M mutation was the most common mutation (28%, $n=12$) followed by L76V (21%, $n=9$), then I47V (7%, $n=3$) and I84V (7%, $n=3$). Among the NRTI associated mutations L74V was the predominant mutation (77%, $n=33$) followed by M184V/I (60%, $n=26$) then TAMS (51%, $n=22$). Of these, 33% of patients ($n=14$) showed NRTI + NNRTI mutations, 39% ($n=17$) showed NRTI + NNRTI + PI mutations, 7% ($n=3$) showed NRTI + PI mutations, whereas 21% ($n=9$) and 2.3% ($n=1$) exclusively showed NRTI and NNRTIs mutations respectively. Twenty-eight samples that had both MiSeq and Sanger sequencing data were available for a comparison of mutational patterns in the PI region. MiSeq sequencing revealed minority PI mutations in 10 samples that were wild type by Sanger sequencing and one sample showed mutations in both Sanger and NGS. The ten samples revealing mutations based on MiSeq data comprised of minority variants including L90M (50%, $n=5$), L76V (20%, $n=2$), I50V (10%, $n=1$), and N88S (20%, $n=2$). Our data suggest that even in the absence of PI mutations based on Sanger data, those minority variants can be present. NGS revealed the presence of PI resistance mutations in patients who had wild-type using population-based sequencing. Given that patient regimen revealed that minority variants were unlikely selected by ART pressure, our results suggest poor adherence as the likely contributor to second-line failure due to the high genetic barrier of PIs. Since ART adherence in these patients was monitored using clinico-immunological parameters and virological tests only when treatment failure was suspected, our results suggest the need for routine virological monitoring. This should provide early opportunity for adherence intervention and thereby avoiding the need for switch to salvage or third-line treatment options, which is more expensive and not readily available in our setting.

A24 Application of large-scale sequencing and data analysis to research on emerging infectious diseases

Yongmei Liu, Tommy Tsan-Yuk Lam, Huachen Zhu, and Yi Guan

State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong SAR, China

Many human diseases are caused by emerging pathogens, such as the SARS and MERS coronaviruses. Timely understanding of the behaviors of these pathogens plays an important role in helping doctors and scientists in searching for treatment methods and designing vaccines. The development of next-generation sequencing (NGS) has led to significant breakthroughs in the production of large amount of unbiased DNA sequence data from field and human clinical samples, providing the capacity